Background: Hyperuricaemia is a risk factor for gout and independently predicts hypertension, diabetes, and chronic kidney disease development. While elevated uric acid levels occur in HIV patients, and weight gain is linked to dolutegravir-based therapy, data on the obesity-hyperuricaemia relationship in this population remain limited.
Objective: The objective of our study was to evaluate the association between obesity and hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.
Methods: Between April 2024 and June 2024, this study conducted a secondary analysis of data on uric acid level and factors associated with obesity from a 2023 cross-sectional study of HIV-positive participants. We used logistic regression to assess the factors associated with hyperuricaemia, and receiver operating characteristic curve analysis to assess the predictive performance of body mass index for hyperuricaemia.
Results: Among 328 participants, hyperuricaemia prevalence was 23.48% (95% confidence interval [CI]: 19.19-28.39%) higher in male participants (31.6%) than female participants (20.0%, = 0.023). Overweight (adjusted odds ratio [aOR]: 2.01; 95% CI: 1.01-4.00; = 0.046), obesity (aOR: 2.50; 95% CI: 1.09-5.73, = 0.030), and male gender (aOR: 2.31; 95% CI: 1.07-5.01, = 0.033) were significantly associated with hyperuricaemia.
Conclusion: Our findings indicate a relationship between hyperuricaemia and obesity in HIV patients on antiretroviral therapy in Uganda. Nationwide studies using primary data are needed to better understand this relationship's epidemiological spread.
What This Study Adds: This study is the first to link obesity with hyperuricaemia among HIV-positive Ugandans on antiretroviral therapy, highlighting obesity as a key metabolic complication of HIV treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886560 | PMC |
| http://dx.doi.org/10.4102/ajlm.v14i1.2565 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Association of systemic lupus and HIV/AIDS: nine observations at the Centre Hospitalier Universitaire de Libreville (Gabon)].
Med Trop Sante Int
December 2024
Service de médecine interne, CHU de Libreville, BP 2228, Libreville, Gabon.
Background: HIV/AIDS infection is endemic in sub-Saharan Africa. It is manifested by a variety of opportunistic diseases that usually occur when the CD4 count is below 200/mm, but also during the immune restoration syndrome (IRS) that occurs under highly active antiretroviral therapy (HAART). Autoimmune and inflammatory diseases are rarely associated with this condition.
View Article and Find Full Text PDFLongitudinal CNS and systemic T-lymphocyte and monocyte activation before and after antiretroviral therapy beginning in primary HIV infection.
Front Immunol
March 2025
Department of Neurology, Yale University School of Medicine, New Haven, CT, United States.
Background: Trafficking of immune cells to the central nervous system is hypothesized to facilitate HIV entry and immune-induced neuronal injury and is mediated by surface proteins such as chemokine receptors and α4 integrin. We longitudinally assessed immune cell activation and surface marker expression in cerebrospinal fluid (CSF) and blood and their relationship with CSF HIV RNA beginning during primary HIV infection (PHI) before and after antiretroviral therapy (ART).
Methods: Longitudinal paired blood and CSF were obtained in ART-naïve PHI (<12 month since infection) participants; some independently initiated ART during follow up.
HIV controllers: hope for a functional cure.
Front Immunol
March 2025
Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Elite controllers (ECs) and post-treatment controllers (PTCs) represent important models for achieving a functional cure for HIV. This review synthesizes findings from immunological, genetic, and virological studies to compare the mechanisms underlying HIV suppression in ECs and PTCs. Although ECs maintain viral control without antiretroviral therapy (ART), PTCs achieve suppression following ART discontinuation.
View Article and Find Full Text PDFTime to initiation of antiretroviral therapy and its predictors among newly diagnosed HIV positive at the selected public health centers in Adama Town, Ethiopia.
AIDS Res Ther
March 2025
Department of Public Health, Adama Hospital Medical College, Adama, Oromia, Ethiopia.
Introduction: Antiretroviral therapy (ART) has significantly reduced HIV infections, but late initiation remains a major issue. This study aimed to identify predictors of ART initiation among newly diagnosed HIV-positive patients in Adama town.
Method: A retrospective cohort study was conducted, with 396 newly diagnosed HIV-positive patients.
High prevalence of low-level viremia among infants initiated on antiretroviral drugs following mother-to-child transmission of HIV.
AIDS Res Ther
March 2025
Joint Clinical Research Center, Plot 101 Lubowa Hill, Kampala, Uganda.
Background: With the current elimination of mother to child transmission (EMTCT) of HIV, the number of HIV-positive newborns has greatly reduced. Some countries have successfully eliminated HIV infections among newborn babies.
Methods: This study was nested within the DRIBS (Drug Resistance testing among Infants at Baseline Study), which enrolled 100 infants at the time of treatment initiation between 2017 and 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!